Positive results in proof-of-concept study to develop a vaccine against Streptococcus suis infection in pigs
Stockholm, April 25, 2022 - Intervacc AB (publ) announces positive results from a proof-of-concept study where piglets from vaccinated sows were protected against experimental challenge with Streptococcus suis. The study showed that piglets from sows that had been vaccinated with a prototype fusion protein vaccine had significantly fewer clinical signs of disease compared to piglets from sows that received a placebo, adjuvant-only, vaccine following challenge with a virulent strain of Streptococcus suis at 4 or 7 weeks of age. “This proof-of-concept study provides a solid foundation